Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Summary

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

Timeline

Start

2022-03-15

Primary completion

2023-10-17

Completion

2024-04-29

Outcome

Outcome not reported

Stopped (Enrollment): “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

Drugs

Indications